Disclaimer

The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Day

March 27, 2025
PRESS RELEASE NON-REGULATED INFORMATION 27 March 2025, 07:00 am CET Ghent, Belgium – 27 March 2025 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, is pleased to announce its participation in the “VFB Happening 2025”...
Read More

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES